GIST Mutation Analysis Exon 9 & Exon 11

Function and Clinical Purpose

Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. Approximately 85% of GISTs harbor mutations in the KIT proto-oncogene. The GIST Mutation Analysis specifically targets Exon 9 and Exon 11 of the KIT gene. These exons encode the regulatory and juxtamembrane domains of the KIT receptor tyrosine kinase. Identifying these mutations is essential for predicting the tumor's behavior and its response to targeted therapies.

Why it is Ordered

This genetic analysis is not a screening tool but a diagnostic and prognostic test ordered after a biopsy has confirmed a GIST. It is ordered to:

• Guide Targeted Therapy: Mutations in Exon 11 generally respond very well to standard doses of Imatinib (Gleevec), whereas Exon 9 mutations often require a higher dose for efficacy.
• Predict Prognosis: Exon 11 mutations are the most common, while Exon 9 mutations are often associated with an intestinal primary site and more aggressive behavior.
• Identify Wild-Type GISTs: If no mutations are found in KIT or PDGFRA, the tumor is considered 'wild-type,' which may require different therapeutic strategies or investigation into rarer genetic syndromes like Carney-Stratakis syndrome.

Associated Conditions

The presence of these mutations is diagnostic for GIST. This information is vital for the multidisciplinary oncology team to determine if a patient is a candidate for neoadjuvant therapy (to shrink a tumor before surgery) or adjuvant therapy (to prevent recurrence after surgery). Understanding the specific exon mutation helps in managing metastatic disease and anticipating potential resistance to certain tyrosine kinase inhibitors.